Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1354-1364

  Sadler, Tammy ^a   Scarpa, Melania ^a,b   Rieder, Florian ^a   West, Gail ^a   Stylianou, Eleni ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cytokines; Epigenetics; Inflammatory bowel disease; Intestinal fibrosis; Type I collagen

Indexed keywords

COLLAGEN TYPE 1; CYTOKINE; RNA POLYMERASE II; VON WILLEBRAND FACTOR;

ACETYLATION; ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; COL1A2 GENE; CONTROLLED STUDY; DNA MODIFICATION; ENDOTHELIUM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; GENE REPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINAL FIBROSIS; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, WESTERN; CELLS, CULTURED; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; COLLAGEN TYPE I; DNA METHYLATION; ENDOTHELIUM, VASCULAR; FIBROSIS; HISTONES; HUMANS; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LYSINE; MESODERM; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA POLYMERASE II; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879102821     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f37a     Document Type: Article

References (44)

1. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235.
2. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006;101:1030-1038.
3. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem. 1995;64:403-434.
4. Ramirez F, Tanaka S, Bou-Gharios G. Transcriptional regulation of the human alpha2 (I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol. 2006;25:365-372.
5. Scarpa M, Stylianou E: Epigenetics: concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis. 2012;18:1982-1996.
6. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature. 2010;465:721-727.
7. Campos EI, Reinberg D. Histones: annotating chromatin. Annu Rev Genet. 2009;43:559-599.
8. Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet. 2010;11:285-296.
9. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39:311-318.
10. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40:897-903.
11. Nightingale KP, Wellinger RE, Sogo JM, et al. Histone acetylation facilitates RNA polymerase II transcription of the Drosophila hsp26 gene in chromatin. EMBO J. 1998;17:2865-2876.
12. Akhtar A, Becker PB. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol Cell. 2000;5:367-375.
13. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823-837.
14. Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14:1790-1800.
15. Bataille F, Rohrmeier C, Bates R, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease, Inflamm Bowel Dis. 2008;14:1514-1527.
16. Flier SN, Tanjore H, Kokkotou EG, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem. 2010;285:20202-20212.
17. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelialtomesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2011;179:2660-2673.
18. Romero LI, Zhang DN, Herron GS, et al. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol. 1997;173:84-92.
19. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002;90:1189-1196.
20. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol. 2003;285:F1060-F1067.
21. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952-961.
22. Hashimoto N, Phan SH, Imaizumi K, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010;43:161-172.
23. Rombouts K, Niki T, Greenwel P, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta (1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res. 2002;278:184-197.
24. Hemmatazad H, Rodrigues HM, Maurer B, et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum. 2009;60:1519-1529.
25. Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation, Biochim Biophys Acta. 2007;1773:1572-1582.
26. Wang Z, Chen C, Finger SN, et al. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J. 2009;34:145-155.
27. McDonald OG, Wu H, Timp W, et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. 2011;18:867-874.
28. Binion DG, West GA, Ina K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997;112:1895-1907.
29. Nowak DE, Tian B, Brasier AR. Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques. 2005;39:715-725.
30. Antoniv TT, De Val S, Wells D, et al. Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2 (I) collagen (COL1A2) gene. J Biol Chem. 2001;276:21754-21764.
31. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 2001;29:e45.
32. Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol. 2007;179:6988-7000.
33. Brookes E, Pombo A. Modifications of RNA polymerase II are pivotal in regulating gene expression states. EMBO Rep. 2009;10:1213-1219.
34. Fraser ID, Germain RN. Navigating the network: signaling cross-talk in hematopoietic cells. Nat Immunol. 2009;10:327-331.
35. Dorigo B, Schalch T, Bystricky K, et al. Chromatin fiber folding: requirement for the histone H4 N-terminal tail. J Mol Biol. 2003;327:85-96.
36. Shogren-Knaak M, Ishii H, Sun JM, et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006;311:844-847.
37. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75-100.
38. Sengupta P, Xu Y, Wang L, et al. Collagen alpha1 (I) gene (COL1A1) is repressed by RFX family. J Biol Chem. 2005;280:21004-21014.
39. Buratowski S. Progression through the RNA polymerase II CTD cycle. Mol Cell. 2009;36:541-546.
40. Tan M, Luo H, Lee S, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146:1016-1028.
41. Gardner KE, Allis CD, Strahl BD. Operating on chromatin, a colorful language where context matters. J Mol Biol. 2011;409:36-46.
42. Henikoff S, Shilatifard A. Histone modification: cause or cog? Trends Genet. 2011;27:389-396.
43. Lefevre GM, Patel SR, Kim D, et al. Altering a histone H3K4 methylation pathway in glomerular podocytes promotes a chronic disease phenotype. PLoS Genet. 2010;6:e1001142.
44. Voigt P, Reinberg D. Histone tails: ideal motifs for probing epigenetics through chemical biology approaches. Chembiochem. 2011;12:236-252.